These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 21334734

  • 1. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S, Gasparini R, Panatto D, Demarteau N.
    Gynecol Oncol; 2011 Jun 01; 121(3):514-21. PubMed ID: 21334734
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 Jun 01; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 3. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 4. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S, Zafar A, Saperi S, Amrizal M.
    Asian Pac J Cancer Prev; 2010 Oct 13; 11(6):1551-9. PubMed ID: 21338196
    [Abstract] [Full Text] [Related]

  • 5. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.
    Cochrane Database Syst Rev; 2018 May 09; 5(5):CD009069. PubMed ID: 29740819
    [Abstract] [Full Text] [Related]

  • 7. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA, Lepetic A, Demarteau N.
    BMC Public Health; 2014 Nov 26; 14():1222. PubMed ID: 25424716
    [Abstract] [Full Text] [Related]

  • 10. [Diseases caused by human papilloma viruses].
    Zollner U, Schwarz TF.
    Dtsch Med Wochenschr; 2011 May 26; 136(20):1067-72. PubMed ID: 21560109
    [Abstract] [Full Text] [Related]

  • 11. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.
    J Natl Cancer Inst; 2012 Nov 21; 104(22):1712-23. PubMed ID: 23104323
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
    Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodríguez AC, Hu S, Sampson JN, Kreimer AR, Costa Rica Vaccine Trial Group.
    Lancet Oncol; 2020 Dec 21; 21(12):1643-1652. PubMed ID: 33271093
    [Abstract] [Full Text] [Related]

  • 13. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.
    Vaccine; 2014 Feb 03; 32(6):733-9. PubMed ID: 24291200
    [Abstract] [Full Text] [Related]

  • 14. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.
    Cancer Prev Res (Phila); 2009 Oct 03; 2(10):868-78. PubMed ID: 19789295
    [Abstract] [Full Text] [Related]

  • 15. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT, Castellsagué X, Garland SM.
    Vaccine; 2012 Nov 20; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [Abstract] [Full Text] [Related]

  • 16. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA, Portnoy A, Campos NG, Sy S, Regan C, Kim JJ.
    Int J Cancer; 2021 Feb 15; 148(4):932-940. PubMed ID: 32706907
    [Abstract] [Full Text] [Related]

  • 17. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
    Jit M, Chapman R, Hughes O, Choi YH.
    BMJ; 2011 Sep 27; 343():d5775. PubMed ID: 21951758
    [Abstract] [Full Text] [Related]

  • 18. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK, Alkhateeb FM.
    Ann Pharmacother; 2009 Apr 27; 43(4):740-4. PubMed ID: 19276314
    [Abstract] [Full Text] [Related]

  • 19. [Continue to use the bivalent HPV vaccine; bivalent vaccine more effective than expected].
    Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2020 Jan 09; 164():. PubMed ID: 32073795
    [Abstract] [Full Text] [Related]

  • 20. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.
    BMC Public Health; 2017 Feb 02; 17(1):152. PubMed ID: 28148228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.